- CITATIONS: 1
|Application ||WB, IHC-P, FC, E|
|Calculated MW||34585 Da|
|Antigen Region||1-27 aa|
|Other Names||Elongation of very long chain fatty acids protein 2, 3-keto acyl-CoA synthase ELOVL2, ELOVL fatty acid elongase 2, ELOVL FA elongase 2, Very-long-chain 3-oxoacyl-CoA synthase 2, ELOVL2, SSC2|
|Target/Specificity||This ELOVL2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1-27 amino acids from the N-terminal region of human ELOVL2.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||ELOVL2 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Catalyzes the first and rate-limiting reaction of the four that constitute the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process, allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids/VLCFAs per cycle. Acts specifically toward polyunsaturated acyl-CoA with the higher activity toward C20:4(n- 6) acyl-CoA. Condensing enzyme that catalyzes the synthesis of polyunsaturated very long chain fatty acid (C20- and C22-PUFA). May participate to the production of polyunsaturated VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators.|
|Cellular Location||Endoplasmic reticulum membrane; Multi-pass membrane protein|
|Tissue Location||Liver and testis.|
Provided below are standard protocols that you may find useful for product applications.
ELOVL2 could be implicated in tissue-specific synthesis of very long chain fatty acids and sphingolipids. This protein may catalyze one or both of the reduction reaction in fatty acid elongation, i.e., conversion of beta-ketoacyl CoA to beta-hydroxyacyl CoA or reduction of trans-2-enoyl CoA to the saturated acyl CoA derivative (By similarity).
Illig,T., et.al., Nat. Genet. 42 (2), 137-141 (2010)
Tanaka,T., et.al., PLoS Genet. 5 (1), E1000338 (2009)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.